INT180451

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 12.65
Pain Relevance 0.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa2) protein folding (Apoa2) transport (Apoa2)
extracellular space (Apoa2) extracellular region (Apoa2)
Anatomy Link Frequency
plasma 2
coronary artery 1
Apoa2 (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 63 99.44 Very High Very High Very High
addiction 7 98.52 Very High Very High Very High
agonist 128 97.68 Very High Very High Very High
Inflammation 36 71.44 Quite High
fibrosis 2 69.84 Quite High
headache 18 28.88 Quite Low
Inflammatory mediators 2 20.72 Low Low
Kinase C 18 5.00 Very Low Very Low Very Low
cytokine 17 5.00 Very Low Very Low Very Low
tolerance 17 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 263 100.00 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

12 99.96 Very High Very High Very High
Pressure And Volume Under Development 117 99.92 Very High Very High Very High
Coronary Artery Disease 168 99.78 Very High Very High Very High
Diabetes Mellitus 526 99.70 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 1 99.30 Very High Very High Very High
Hypercholesterolemia 1 99.24 Very High Very High Very High
Renal Disease 8 99.04 Very High Very High Very High
Hyperlipidemia 23 97.40 Very High Very High Very High
Cataract 1 97.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pioglitazone also improves diabetic dyslipidemia, increasing high-density lipoprotein (HDL) cholesterol, reducing plasma triglycerides, and causing a shift from small dense low-density lipoprotein (LDL) to larger more buoyant LDL.
Positive_regulation (increasing) of HDL in plasma associated with diabetes mellitus and disorder of lipid metabolism
1) Confidence 0.67 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 1.05 Pain Relevance 0.10
Pioglitazone significantly increased HDL and lowered triglycerides compared with rosiglitazone.50 These differences in plasma lipids may, in part, explain the adverse cardiovascular signal that has been reported with rosiglitazone.59,60

Pioglitazone dose-response effect

Positive_regulation (increased) of HDL in plasma associated with disorder of lipid metabolism
2) Confidence 0.67 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.73 Pain Relevance 0.05
Although there was some degree of dose dependence in the effect of dalcetrapib on HDL-C in other phase II trials,18–20 the increase in HDL-C observed with dalcetrapib 600 mg in combination with a statin (pravastatin) was as high as 31.4% at 12 weeks of treatment.20 This is only slightly below the increases observed in the current study with dalcetrapib 900 mg (33.4% at Week 24; 33.8% at Week 48).
Positive_regulation (increase) of HDL associated with addiction and disorder of lipid metabolism
3) Confidence 0.67 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 0.42 Pain Relevance 0.05
Subjects with CAD had lower concentration of HDL-C and higher concentration of triglyceride as compared to those without CAD (Table 2).


Positive_regulation (concentration) of HDL associated with coronary artery disease and disorder of lipid metabolism
4) Confidence 0.49 Published 2005 Journal Lipids Health Dis Section Body Doc Link PMC545942 Disease Relevance 1.69 Pain Relevance 0
Elevated VLDL and LDL with depressed HDL (unpublished data) and renal dysfunction with microalbuminuria along with cataracts and other complications associated with progressive diabetes were also observed (data not shown).


Positive_regulation (Elevated) of HDL associated with diabetes mellitus, renal disease, cataract and disorder of lipid metabolism
5) Confidence 0.49 Published 2010 Journal Nutr Metab (Lond) Section Body Doc Link PMC2868017 Disease Relevance 1.00 Pain Relevance 0
The latter is a key intermediate in cholesterol synthesis and aids in decreasing LDL cholesterol and increasing HDL cholesterol levels [239, 240].
Positive_regulation (increasing) of HDL associated with acquired immune deficiency syndrome or hiv infection and disorder of lipid metabolism
6) Confidence 0.45 Published 2010 Journal The Open Biochemistry Journal Section Body Doc Link PMC2864432 Disease Relevance 0.49 Pain Relevance 0
Dalcetrapib effectively increased HDL-C over 48 weeks of treatment.



Positive_regulation (increased) of HDL associated with disorder of lipid metabolism
7) Confidence 0.45 Published 2010 Journal European Heart Journal Section Abstract Doc Link PMC2821630 Disease Relevance 0.36 Pain Relevance 0.04
Clinical studies have shown that dalcetrapib either alone or with pravastatin was associated with increased HDL-C but no effect on BP.18,19 A recent analysis of safety data at 4 and 12 weeks from five phase II trials further reinforces the safety of dalcetrapib both alone and in combination with statins20 and supported further clinical study of dalcetrapib.
Positive_regulation (increased) of HDL associated with pressure and volume under development and disorder of lipid metabolism
8) Confidence 0.45 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 0.98 Pain Relevance 0
Dalcetrapib increased HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (–53.5%, Week 24; –56.5%, Week 48), and increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48).
Positive_regulation (increased) of HDL associated with disorder of lipid metabolism
9) Confidence 0.45 Published 2010 Journal European Heart Journal Section Abstract Doc Link PMC2821630 Disease Relevance 0.35 Pain Relevance 0.05
There was a significantly greater increase in HDL-C from baseline with dalcetrapib at Weeks 24 and 48 (each P < 0.0001 vs. placebo; Table 2).
Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
10) Confidence 0.45 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 0.54 Pain Relevance 0
Decreased plasma levels of CETP are associated with increased levels of HDL-C and, in turn, decreased risk of coronary artery disease (CAD).8–10 These effects have been correlated also with specific mutations in the CETP gene.8,11,12
Positive_regulation (increased) of HDL in coronary artery associated with coronary artery disease and disorder of lipid metabolism
11) Confidence 0.45 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 1.30 Pain Relevance 0
Additionally, in contrast with torcetrapib, the observed increase in HDL-C with dalcetrapib reached a maximum at approximately 2 weeks; torcetrapib showed a continuing increase in HDL-C after 3 months of treatment in the ILLUMINATE trial.13
Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
12) Confidence 0.45 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 0.59 Pain Relevance 0.06
Usually, in the case of type 2 diabetes, patients are taking lipid lowering drugs in order to ameliorate their lipid profile, namely lower triglyceride level and increase HDL-C concentration.
Positive_regulation (increase) of HDL associated with diabetes mellitus and disorder of lipid metabolism
13) Confidence 0.45 Published 2005 Journal Lipids Health Dis Section Body Doc Link PMC545942 Disease Relevance 0.99 Pain Relevance 0
increased total CHOL, HDL-c, and ?
Positive_regulation (increased) of HDL associated with disorder of lipid metabolism
14) Confidence 0.20 Published 2007 Journal PPAR Research Section Body Doc Link PMC1940322 Disease Relevance 0.42 Pain Relevance 0.47
ApoA-II, resulting in raising HDL cholesterol levels in humans [31, 32].
Positive_regulation (resulting) of ApoA-II associated with disorder of lipid metabolism
15) Confidence 0.07 Published 2008 Journal PPAR Research Section Body Doc Link PMC2435221 Disease Relevance 0.76 Pain Relevance 0.03
Notably, Szapary et al. have shown that pioglitazone treatment for 12 weeks significantly increased Apo-AII by 7.7% [35] while Qin et al. demonstrated that pioglitazone stimulates Apo-AI production in HepG2 cells by through PPAR?
Positive_regulation (increased) of Apo-AII
16) Confidence 0.02 Published 2009 Journal PPAR Research Section Body Doc Link PMC2729049 Disease Relevance 0.71 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox